Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Atara Biotherapeutics ( (ATRA) ) has provided an update.
On June 10, 2025, Atara Biotherapeutics held its annual stockholders meeting, where several key decisions were made. The election of directors resulted in the appointment of three nominees to serve until 2028. Additionally, stockholders approved the executive compensation plan and decided to hold annual advisory votes on this matter. Deloitte & Touche LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2025.
The most recent analyst rating on (ATRA) stock is a Buy with a $13.00 price target. To see the full list of analyst forecasts on Atara Biotherapeutics stock, see the ATRA Stock Forecast page.
Spark’s Take on ATRA Stock
According to Spark, TipRanks’ AI Analyst, ATRA is a Neutral.
Atara Biotherapeutics faces significant financial challenges with high leverage and negative equity, which are major concerns. Positive technical indicators and recent corporate events, such as strategic restructuring and regulatory progress, provide some optimism, but the overall outlook remains cautious given the financial instability.
To see Spark’s full report on ATRA stock, click here.
More about Atara Biotherapeutics
Atara Biotherapeutics, Inc. operates in the biopharmaceutical industry, focusing on developing therapies for patients with serious diseases, including cancer and autoimmune conditions.
Average Trading Volume: 58,644
Technical Sentiment Signal: Sell
Current Market Cap: $61.98M
See more insights into ATRA stock on TipRanks’ Stock Analysis page.